((自动化翻译由路透提供，请见免责声明 ))
11月5日 - ** 癌症测试制造商Exact Sciences 股价盘后下跌27.3%，至52美元
** 下调2024年总营收预期；介于27.3亿美元至27.5亿美元之间，此前预期为28.1亿美元至28.5亿美元
** 公司公布的第三季度营收为 7.09 亿美元，低于预期的 7.177 亿美元。
** 将筛选部门的收入指导从之前的 21.6 亿至 21.8 亿美元下调至 20.8 亿至 21 亿美元
** 我们在第三季度的执行情况和更新的全年展望没有反映出我们的全部潜力。我们计划在 2025 年加速增长，我们的长期前景依然强劲。
** 截至上次收盘，公司股价累计下跌 3.3
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.